ZymIQ receives positive decision from the European Patent Office
Prenumeration
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
ZymIQ announced today that the European Patent Office (EPO) has confirmed that no opposition has been filed against the company’s granted patent EP4380549. The patent, granted on November 13, 2024, is valid until 2043. This decision means the patent now stands firm and further strengthens ZymIQ’s intellectual property position within enzyme-based medical technology for the respiratory tract.
The patented technology forms the basis of ViruPrev®, an enzyme-based nasal spray under development within the framework of the EU Medical Device Regulation (MDR). ViruPrev® is designed to create a protective layer inside the nasal cavity—the primary entry point for many respiratory viruses, including coronaviruses. The product is part of ZymIQ’s portfolio of enzyme-based barrier solutions that support the body’s natural defenses in the skin, oral cavity, and airways.
In vitro data demonstrate strong virucidal effect
Independent laboratory tests conducted by a well-recognized, certified US laboratory show that ViruPrev® Nasal Spray safely and rapidly reduced SARS-CoV-2 levels by more than 99.9%. The results demonstrate that ViruPrev® acts as a physical and enzymatic barrier, binding and inactivating virus particles.
As the nasal cavity is a major entry and transmission route for respiratory viruses, ViruPrev® is expected to serve as a complement to vaccination and other preventive measures. The product is not yet CE-marked, and clinical studies are planned before market launch.
“Having our patent confirmed without opposition is an important milestone for ZymIQ. It validates the value of our enzyme technology and strengthens our position in future collaborations and partnerships. We see great potential for ViruPrev® as a complement to our other barrier products within oral and dermal health,” says Michael Edelborg Christensen, CEO of ZymIQ Technology AB.